Now livetag icon
What will define the 2026 holiday season? 🔎 See how shoppers are deciding. Download the report →banner icon
OPDIVO

March 2026

OPDIVO Market Share Analysis for March 2026

View efficacy information for OPDIVO® (nivolumab) in previously treated metastatic non-small cell lung cancer. Please see Indications and Important Safety Information.
Year Founded--
Employees> 10001
Annual Revenue$2M - $5M
opdivohcp.com
OPDIVO
OPDIVO (including company regionals)
  • opdivohcp.com
    opdivohcp.com
See more website traffic and engagement information

OPDIVO Revenue up to March 2026 is 2M - 5M

revenue generated by OPDIVO top domains

OPDIVO top domains revenue over 3 years

Revenue for OPDIVO top domains


Total visits to OPDIVO's top domains

Understand OPDIVO market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

Avg. visit duration in OPDIVO's top domains

Analyze OPDIVO engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

Avg. pageviews on OPDIVO's top domains

See how OPDIVO keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

Want to gain deeper traffic insights?

Filter 20.3M+ online businesses. Discover new leads when their traffic spikes, when they start or stop using technologies, or when they get positive press.



Top technologies used by OPDIVO

These are the website technologies, by industry, used by OPDIVO top domains

Conversion & Analytics (10)

Google Analytics

Google Analytics

Advertising (7)

DoubleClick

DoubleClick

Audio Video Media (4)

VideoJS

VideoJS

Marketing (2)

Google Marketing Platform

Google Marketing Platform

More Technologies

7

See all

Ready to discover high quality prospects?

Identify what technologies a website uses to craft the perfect sales pitch, and shorten the sales cycle with the Similarweb Sales Intelligence Solution.


News & Signals from OPDIVO

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOpdivo attends event 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.Neoadjuvant nivolumab (Opdivo) in combination with chemotherapy elicited a statistically significant and clinically meaningful overall survival (OS) improvement vs chemotherapy alone in patients with resectable non - small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

See all OPDIVO signals

Focus your sales teams on the most promising opportunities. By prioritizing opportunities and engaging at the right time, you can optimize efforts and close more deals.